More interestingly, in rapamycin-resistant TSC2-depleted cells, the sensitivities to MK1775 and the combination of MK1775 and rapamycin were similar to those in parental TSC2-depleted cells, suggesting that this new strategy might be used to overcome rapamycin resistance in TSC patients due to its novel mechanism of action. This evidence concerns the gene TSC2 and tuberous sclerosis.